Cerebrospinal fluid β-amyloid 1-42 and tau in control subjects at risk for Alzheimer's disease: The effect of APOE ε4 allele

Biological Psychiatry

Volumn 56, Issue 9, 2004, Pages 670-676

  Sunderland, Trey ^a   Mirza, Nadeem ^a   Putnam, Karen T ^a   Linker, Gary ^a   Bhupali, Deepa ^a   Durham, Rob ^d   Soares, Holly ^d   Kimmel, Lida ^d   Friedman, David ^d   Bergeson, Judy ^a   Csako, Gyorgy ^b   Levy, James A ^a   Bartko, John J ^c   Cohen, Robert M ^a  

^a NATIONAL INSTITUTE OF MENTAL HEALTH   (United States)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

^c Bethesda   (United States)

^d PFIZER INC   (United States)

Author keywords

amyloid; Alzheimer's disease; APOE; Cerebrospinal fluid; tau

Indexed keywords

AMYLOID BETA PROTEIN[1-42]; APOLIPOPROTEIN E; APOLIPOPROTEIN E EPSILON 4; BIOLOGICAL MARKER; TAU PROTEIN; UNCLASSIFIED DRUG;

ADULT; AGED; ALLELE; ALZHEIMER DISEASE; ARTICLE; CEREBROSPINAL FLUID; CONTROLLED STUDY; FAMILY HISTORY; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL RESEARCH; MENTAL HEALTH SERVICE; NEUROIMAGING; PRIORITY JOURNAL; PSYCHOLOGIC TEST; RISK ASSESSMENT;

AGE FACTORS; AGED; ALLELES; ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN; APOLIPOPROTEIN E4; APOLIPOPROTEINS E; CHI-SQUARE DISTRIBUTION; DEMOGRAPHY; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; GENOTYPE; HUMANS; MALE; MIDDLE AGED; NEUROPSYCHOLOGICAL TESTS; PEPTIDE FRAGMENTS; RISK; SPINAL PUNCTURE; TAU PROTEINS;

EID: 7444271086     PISSN: 00063223     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.biopsych.2004.07.021     Document Type: Article

References (50)

1. N. Andreasen, L. Minthon, P. Davidsson, E. Vanmechelen, H. Vanderstichele, B. Winblad, K. Blennow Evaluation of CSF-tau and CSF-Abeta42 as diagnostic markers for Alzheimer disease in clinical practice Arch Neurol 58 2001 373 379
2. J.R. Blair, O. Spreen Predicting premorbid IQ A revision of the National Adult Reading Test Clin Neuropsychol 3 1989 129 136
3. K. Blennow Cerebrospinal fluid protein biomarkers for Alzheimer's disease J Am Soc Exp Neurother 1 2004 213 225
4. H. Braak, E. Braak Neuropathological staging of Alzheimer-related changes Acta Neuropathol Appl Neurobiol 14 1991 39 44
5. K. Buerger, R. Zinkowski, S.J. Teipel, T. Tapiola, H. Arai, K. Blennow Differential diagnosis of Alzheimer disease with cerebrospinal fluid levels of tau protein phosphorylated at threonine 231 Arch Neurol 59 2002 1267 1272
6. D.B. Carter, E. Dunn, D.D. McKinley, N.C. Stratman, T.P. Boyle, S.L. Kuiper Human apolipoprotein E4 accelerates beta-amyloid deposition in APPsw transgenic mouse brain Ann Neurol 50 2001 468 475
7. R.J. Caselli, D. Osborne, E.M. Reiman, J.G. Hentz, C.J. Barbieri, A.M. Saunders Preclinical cognitive decline in late middle-aged asymptomatic apolipoprotein E-e4/4 homozygotes A replication study J Neurol Sci 189 2001 93 98
8. J. Cohen Statistical Power Analysis for the Behavioral Sciences 2nd ed 1988 Lawrence Erlbaum Associates New York
9. R.B. DeMattos, K.R. Bales, D.J. Cummins, S.M. Paul, D.M. Holtzman Brain to plasma amyloid-beta efflux A measure of brain amyloid burden in a mouse model of Alzheimer's disease Science 295 2002 2264 2267
10. A.M. Fagan, L.H. Younkin, J.C. Morris, J.D. Fryer, T.G. Cole, S.G. Younkin, D.M. Holtzman Differences in the Abeta40/Abeta42 ratio associated with cerebrospinal fluid lipoproteins as a function of apolipoprotein E genotype Ann Neurol 48 2000 201 210
11. M.F. Folstein, S.E. Folstein, P.R. McHugh Mini-mental state. A practical method for grading the cognitive state of patients for the clinician J Psychiatr Res 12 1975 189 198
12. N.C. Fox, E.K. Warrington, A.L. Seiffer, S.K. Agnew, M.N. Rossor Presymptomatic cognitive deficits in individuals at risk of familial Alzheimer's disease. A longitudinal prospective study Brain 121 1998 1631 1639
13. P. Greenwood, T. Sunderland, J. Friz, R. Parasuraman Genetics and visual attention Selective deficits in healthy adult carriers of the E4 allele of the apolipoprotein E gene Proc Natl Acad Sci U S A 97 2000 11661 11666
14. J. Hardy, D.J. Selkoe The amyloid hypothesis of Alzheimer's disease Progress and problems on the road to therapeutics Science 297 2002 353 356
15. C.P. Hughes, L. Berg, W.L. Danziger, L.A. Coben, R.L. Martin A new clinical scale for the staging of dementia Br J Psychiatry 140 1982 566 572
16. F. Hulstaert, K. Blennow, A. Ivanoiu, H.C. Schoonderwaldt, M. Riemenschneider, P.P. De Deyn Improved discrimination of AD patients using beta-amyloid(1-42) and tau levels in CSF Neurology 52 1999 1555 1562
17. E.F. Kaplan, H. Goodglass, S. Weintraub The Boston Naming Test 1983 Lea & Febiger Philadelphia
18. T. Kawarabayashi, L.H. Younkin, T.C. Saido, M. Shoji, K.H. Ashe, S.G. Younkin Age-dependent changes in brain, CSF and plasma amyloid (beta) protein in the Tg2576 transgenic mouse model of Alzheimer's disease J Neurosci 21 2001 372 381
19. W.E. Klunk, H. Engler, A. Nordberg, Y. Wang, G. Blomqvist, D.P. Holt Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B Ann Neurol 55 2004 306 319
20. D.S. Knopman, S.T. DeKosky, J.L. Cummings, H. Chui, J. Corey-Bloom, N. Relkin Practice parameterDiagnosis of dementia (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology Neurology 56 2001 1143 1153
21. J. Levy, J.L. Bergeson, K.T. Putnam, V. Rosen, R. Cohen, F. Lalonde Context-specific memory and apolipoprotein E (ApoE) E4 Cognitive evidence from the NIMH prospective study of risk for Alzheimer's disease J Int Neuropsychol Soc 10 2004 362 370
22. A. Lim, D. Tsuang, W. Kukull, D. Nochlin, J. Leverenz, W. McCormick Clinico-neuropathological correlation of Alzheimer's disease in a community-based case series J Am Geriatr Soc 47 1999 564 569
23. G. Linker, N. Mirza, G. Manetti, M. Meyer, K.T. Putnam, T. Sunderland Fine-needle, negative-pressure lumbar puncture A safe technique for collecting CSF Neurology 59 2002 2008 2009
24. S. Mattis Mental status examination for organic mental syndrome in the elderly patient L. Bellak T. Karasu Geriatric Psychiatry 1976 Grune & Stratton New York
25. G. McKhann, D. Drachman, M. Folstein, R. Katzman, D. Price, E.M. Stadlan Clinical diagnosis of Alzheimer's disease Report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease Neurology 34 1984 939 944
26. P.D. Mehta, T. Pirttila, S.P. Mehta, E.A. Sersen, P.S. Aisen, H.M. Wisniewski Plasma and cerebrospinal fluid levels of amyloid beta proteins 1-40 and 1-42 in Alzheimer disease Arch Neurol 57 2000 100 105
27. M.F. Mendez, A.R. Mastri, J.H. Sung, W.H. Frey 2nd Clinically diagnosed Alzheimer disease Neuropathologic findings in 650 cases Alzheimer Dis Assoc Disord 6 1992 35 43
28. S.S. Mirra, A. Heyman, D. McKeel, S.M. Sumi, B.J. Crain, L.M. Brownlee The Consortium to Establish a Registry for Alzheimer's Disease (CERAD). Part II. Standardization of the neuropathologic assessment of Alzheimer's disease Neurology 41 1991 479 486
29. J. Naslund, V. Haroutunian, R. Mohs, K.L. Davis, P. Davies, P. Greengard, J.D. Buxbaum Correlation between elevated levels of amyloid beta-peptide in the brain and cognitive decline JAMA 283 2000 1571 1577
30. K.L. Newell, B.T. Hyman, J.H. Growdon, E.T. Hedley-Whyte Application of the National Institute on Aging (NIA)-Reagan Institute criteria for the neuropathologic diagnosis of Alzheimer disease J Neuropathol Exp Neurol 58 1999 1147 1155
31. R.M. Nitsch, G.W. Rebeck, M. Deng, U.I. Richardson, M. Tennis, D.B. Schenk Cerebrospinal fluid levels of amyloid beta-protein in Alzheimer's disease Inverse correlation with severity of dementia and effect of apolipoprotein E genotype Ann Neurol 37 1995 512 518
32. N. Okamura, H. Arai, M. Maruyama, M. Higuchi, T. Matsui, H. Tanji Combined analysis of CSF tau levels and [(123)I]iodoamphetamine SPECT in mild cognitive impairment Implications for a novel predictor of Alzheimer's disease Am J Psychiatry 159 2002 474 476
33. R.C. Peterson Mild cognitive impairment as a diagnostic entity J Intern Med 256 2004 183 194
34. J.A. Prince, H. Zetterberg, N. Andreasen, J. Marcusson, K. Blennow APOE epsilon4 allele is associated with reduced cerebrospinal fluid levels of Abeta42 Neurology 62 2004 2116 2118
35. E.M. Reiman, R.J. Caselli, L.S. Yun, K. Chen, D. Bandy, S. Minoshima Preclinical evidence of Alzheimer's disease in persons homozygous for the epsilon 4 allele for apolipoprotein E N Engl J Med 334 1996 752 758 [see comments]
36. B. Reisberg, S.H. Ferris, M.J. de Leon, T. Crook The Global Deterioration Scale for assessment of primary degenerative dementia Am J Psychiatry 139 1982 1136 1139
37. M. Riemenschneider, N. Lautenschlager, S. Wagenpfeil, J. Diehl, A. Drzezga, A. Kurz Cerebrospinal fluid tau and beta-amyloid 42 proteins identify Alzheimer disease in subjects with mild cognitive impairment Arch Neurol 59 2002 1729 1734
38. A.M. Saunders, M.K. Trowers, R.A. Shimkets, S. Blakemore, D.J. Crowther, T.A. Mansfield The role of apolipoprotein E in Alzheimer's disease Pharmacogenomic target selection Biochim Biophys Acta 1502 2000 85 94
39. D. Schenk, R. Barbour, W. Dunn, G. Gordon, H. Grajeda, T. Guido Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse Nature 400 1999 173 177 [see comments]
40. D.J. Selkoe The origins of Alzheimer disease A is for amyloid JAMA 283 2000 1615 1617
41. K. Shoghi-Jadid, G.W. Small, E.D. Agdeppa, V. Kepe, L.M. Ercoli, P. Siddarth Localization of neurofibrillary tangles and beta-amyloid plaques in the brains of living patients with Alzheimer disease Am J Geriatr Psychiatry 10 2002 24 35
42. M. Sjogren, H. Vanderstichele, H. Agren, O. Zachrisson, M. Edsbagge, C. Wikkelso Tau and Abeta42 in cerebrospinal fluid from healthy adults 21-93 years of age establishment of reference values Clin Chem 47 2001 1776 1781
43. I. Skoog, P. Davidsson, O. Aevarsson, H. Vanderstichele, E. Vanmechelen, K. Blennow Cerebrospinal fluid beta-amyloid 42 is reduced before the onset of sporadic dementia A population-based study in 85-year-olds Dement Geriatr Cogn Disord 15 2003 169 176
44. G.W. Small, L.M. Ercoli, D.H.S. Silverman, S.C. Huang, S. Komo, S.Y. Bookheimer Cerebral metabolic and cognitive decline in persons at genetic risk for Alzheimer's disease Proc Natl Acad Sci 97 2000 6037 6042
45. T. Sunderland, R. Dukoff Surrogate decision-making and advanced directives with cognitively-impaired research subjects H.A. Pincus Informed Consent A Resource Manual for Investigators 1999 American Psychiatric Press Washington, DC
46. T. Sunderland, G. Linker, N. Mirza, K.T. Putnam, D.L. Friedman, L.H. Kimmel Decreased beta-amyloid1-42 and increased tau levels in cerebrospinal fluid of patients with Alzheimer disease JAMA 289 2003 2094 2103
47. T. Tapiola, T. Pirttila, P.D. Mehta, I. Alafuzofff, M. Lehtovirta, H. Soininen Relationship between apoE genotype and CSF beta-amyloid (1-42) and tau in patients with probable and definite Alzheimer's disease Neurobiol Aging 21 2000 735 740
48. L.C. Walker, J. Pahnke, M. Madauss, S. Vogelgesang, A. Pahnke, E.W. Herbst Apolipoprotein E4 promotes early deposition of Abeta42 and then Abeta40 in the elderly Acta Neuropathol (Berl) 100 2000 36 42
49. R.W. Warzok, C. Kessler, G. Apel, A. Schwarz, R. Egensperger, D. Schreiber Apolipoprotein E4 promotes incipient Alzheimer pathology in the elderly Alzheimer Dis Assoc Disord 12 1998 33 39
50. Y.Y. Wu, R. Delgado, R. Costello, T. Sunderland, R. Dukoff, G. Csako Quantitative assessment of apolipoprotein E genotypes by image analysis of PCR-RFLP fragments Clin Chim Acta 293 2000 213 221